Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | PDE10A | Q9Y233 | 5/20 | 0.48 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2482700 | 0.92 | PDE10A (0.49) | KMT2APDE10A | |
| SCHEMBL2485240 | 0.87 | PDE10A (0.52) | KMT2APDE10A | |
| SCHEMBL2486064 | 0.83 | KMT2A (0.54) | KMT2APDE10AHSD17B14KDM4EPOLB | |
| SCHEMBL8382992 | 0.83 | KMT2A (0.54) | KMT2APDE10AHSD17B14KDM4EPOLB | |
| SCHEMBL11609875 | 0.80 | KMT2A (0.71) | KMT2AHSD17B14KDM4EPOLBMAPT | |
| SCHEMBL1303247 | 0.78 | PDE10A (0.76) | PDE10A | |
| SCHEMBL16460100 | 0.78 | KMT2A (0.78) | KMT2AHSD17B14KDM4EMAPT | |
| SCHEMBL31135050 | 0.78 | KMT2A (0.78) | KMT2AHSD17B14KDM4EMAPT | |
| SCHEMBL2487837 | 0.74 | PDE10A (0.65) | PDE10A | |
| SCHEMBL3347086 | 0.74 | RAB9A (0.68) | KMT2AKDM4EPOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2376455-B1 | AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC (US) | 2012-11-14 | — | — | EP | claimed |
| EP-2376455-A1 | AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2011-10-19 | — | — | EP | claimed |
| WO-2010077992-A1 | AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-07-08 | — | — | WO | claimed |
| US-20100160280-A1 | AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-06-24 | — | — | US | claimed |
| US-8637500-B2 | Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637500-B2 | Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637500-B2 | Aminopyridine and carboxypyridine compounds as phosphodiesterase 10 inhibitors | AMGEN INC. (US) | 2014-01-28 | — | — | US | disclosed |
| EP-2376455-B1 | AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC (US) | 2012-11-14 | — | — | EP | disclosed |
| EP-2376455-B1 | AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC (US) | 2012-11-14 | — | — | EP | disclosed |
| EP-2376455-A1 | AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | Amgen Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010077992-A1 | AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-07-08 | — | — | WO | disclosed |
| US-20100160280-A1 | AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100160280-A1 | AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-06-24 | — | — | US | disclosed |
| US-20100160280-A1 | AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | AMGEN INC. (US) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160280-A1 | AMINOPYRIDINE AND CARBOXYPYRIDINE COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS | PDE4A, PDE7A, PDE4D | KMT2A 2462/4885PDE10A 10/4885HSD17B14 1691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.